NASDAQ:ADMAADMA Biologics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding ADMA Biologics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $2.83 -0.04 (-1.39 %) (As of 07/10/2020 04:00 PM ET) Add Compare Share Today's Range$2.80Now: $2.83▼$2.8950-Day Range$2.80MA: $2.96▼$3.2952-Week Range$1.45Now: $2.83▼$5.48Volume2.27 million shsAverage Volume2.14 million shsMarket Capitalization$244.37 millionP/E RatioN/ADividend YieldN/ABeta2.07 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media ADMA Biologics, Inc., a biopharmaceutical and specialty immunoglobulin company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease. The company also offers Nabi-HB, a hyperimmune globulin for the treatment of acute exposure; and Bivigam, an intravenous immune globulin for the treatment of primary humoral immunodeficiency. In addition, it operates source plasma collection facilities in Norcross, Marietta, and Kennesaw, Georgia. The company distributes its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was founded in 2004 and is headquartered in Ramsey, New Jersey.Read More Beat the Market (BTM) Rank™ 3.4 Analyst's Opinion Consensus RatingADMA Biologics has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $7.25, ADMA Biologics has a potential upside of 156.2% from its current price of $2.83.Amount of Analyst CoverageADMA Biologics has only been the subject of 3 research reports in the past 90 days. Previous Next 3.0 Community Rank Outperform VotesADMA Biologics has received 356 “outperform” votes. (Add your “outperform” vote.)Underperform VotesADMA Biologics has received 239 “underperform” votes. (Add your “underperform” vote.)Community SentimentADMA Biologics has received 59.83% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about ADMA Biologics and other stocks. Vote “Outperform” if you believe ADMA will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ADMA will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldADMA Biologics does not currently pay a dividend.Dividend GrowthADMA Biologics does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ADMA Biologics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 11.70% of the stock of ADMA Biologics is held by insiders.Percentage Held by Institutions56.12% of the stock of ADMA Biologics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for ADMA Biologics are expected to grow in the coming year, from ($0.80) to ($0.33) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ADMA Biologics is -3.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ADMA Biologics is -3.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioADMA Biologics has a P/B Ratio of 6.43. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.4Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.60 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ADMA Previous Symbol CUSIPN/A CIK1368514 Webwww.admabiologics.com Phone201-478-5552Debt Debt-to-Equity Ratio1.02 Current Ratio11.90 Quick Ratio8.14Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$29.35 million Price / Sales8.33 Cash FlowN/A Price / Cash FlowN/A Book Value$0.44 per share Price / Book6.43Profitability EPS (Most Recent Fiscal Year)($0.92) Net Income$-48,280,000.00 Net Margins-151.18% Return on Equity-105.97% Return on Assets-35.21%Miscellaneous Employees314 Outstanding Shares86,350,000Market Cap$244.37 million Next Earnings Date8/13/2020 (Estimated) OptionableOptionable NASDAQ:ADMA Rates by TradingView Receive ADMA News and Ratings via Email Sign-up to receive the latest news and ratings for ADMA and its competitors with MarketBeat's FREE daily newsletter. ADMA Biologics (NASDAQ:ADMA) Frequently Asked Questions How has ADMA Biologics' stock been impacted by COVID-19 (Coronavirus)? ADMA Biologics' stock was trading at $2.31 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ADMA stock has increased by 22.5% and is now trading at $2.83. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of ADMA Biologics? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ADMA Biologics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for ADMA Biologics. When is ADMA Biologics' next earnings date? ADMA Biologics is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for ADMA Biologics. How were ADMA Biologics' earnings last quarter? ADMA Biologics Inc (NASDAQ:ADMA) announced its earnings results on Wednesday, May, 6th. The biotechnology company reported ($0.26) EPS for the quarter, missing the Zacks' consensus estimate of ($0.13) by $0.13. The biotechnology company earned $10.20 million during the quarter, compared to analyst estimates of $10.71 million. ADMA Biologics had a negative return on equity of 105.97% and a negative net margin of 151.18%. View ADMA Biologics' earnings history. What price target have analysts set for ADMA? 4 brokers have issued 1-year price targets for ADMA Biologics' stock. Their forecasts range from $4.00 to $12.00. On average, they expect ADMA Biologics' share price to reach $7.25 in the next twelve months. This suggests a possible upside of 156.2% from the stock's current price. View analysts' price targets for ADMA Biologics. What are Wall Street analysts saying about ADMA Biologics stock? Here are some recent quotes from research analysts about ADMA Biologics stock: 1. According to Zacks Investment Research, "ADMA Biologics, Inc. is a specialty immune globulin company. It develops, manufactures and intends to market plasma-based biologics for the treatment and prevention of certain infectious diseases. The Company's target patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease or who may be immune-suppressed for medical reasons. Its lead product candidate, RI-002, which is in Phase III clinical trial, is intended for the treatment of primary immune deficiency disease. ADMA Biologics, Inc. is headquartered in Ramsey, New Jersey. " (6/9/2020) 2. Maxim Group analysts commented, "ADMA announced (8/22) that the relaunch of BIVIGAM has commenced. BIVIGAM is available through authorized distributor BioCareSD (Private). Launch for ASCENIV should follow in 2H19." (8/27/2019) Has ADMA Biologics been receiving favorable news coverage? Press coverage about ADMA stock has trended somewhat positive on Sunday, InfoTrie Sentiment reports. The research firm scores the sentiment of media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. ADMA Biologics earned a news sentiment score of 1.3 on InfoTrie's scale. They also assigned headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View the latest news about ADMA Biologics. Who are some of ADMA Biologics' key competitors? Some companies that are related to ADMA Biologics include BioCryst Pharmaceuticals (BCRX), Atara Biotherapeutics (ATRA), BAVARIAN NORDIC/S (BVNRY), Replimune Group (REPL), Vericel (VCEL), Cellectis (CLLS), Krystal Biotech (KRYS), Osiris Therapeutics (OSIR), Proteon Therapeutics (PRTO), Agenus (AGEN), Avrobio (AVRO), Aerie Pharmaceuticals (AERI), Autolus Therapeutics (AUTL), Vaxart (VXRT) and AVITA MED LTD/S (RCEL). View all competitors. What other stocks do shareholders of ADMA Biologics own? Based on aggregate information from My MarketBeat watchlists, some companies that other ADMA Biologics investors own include Amplify Energy (AMPY), Amplify Energy (AMPY), Trevena (TRVN), Nokia Oyj (NOK), Matinas BioPharma (MTNB), Chesapeake Energy (CHK), Miragen Therapeutics (MGEN), Tilly's (TLYS), Unum Therapeutics (UMRX) and OrganiGram (OGI). Who are ADMA Biologics' key executives? ADMA Biologics' management team includes the following people: Mr. Adam S. Grossman, Co-Founder, Pres, CEO & Director (Age 42)Dr. Jerrold B. Grossman Ph.D., D.P.S., Co-Founder & Vice Chairman (Age 71)Mr. Brian Lenz CPA, CPA, Exec. VP & CFO (Age 47)Dr. James Mond, Exec. VP, Chief Scientific Officer & Chief Medical Officer (Age 73)Mr. James Hauert, Sr. VP of Commercialization & Strategy What is ADMA Biologics' stock symbol? ADMA Biologics trades on the NASDAQ under the ticker symbol "ADMA." Who are ADMA Biologics' major shareholders? ADMA Biologics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Exane Derivatives (0.03%). Company insiders that own ADMA Biologics stock include Adam S Grossman, Biotest Divestiture Trust, Brian Lenz, James Mond, Lawrence P Guiheen, Life Sciences Maste Perceptive and Perceptive Advisors Llc. View institutional ownership trends for ADMA Biologics. Which institutional investors are buying ADMA Biologics stock? ADMA stock was bought by a variety of institutional investors in the last quarter, including Exane Derivatives. Company insiders that have bought ADMA Biologics stock in the last two years include Adam S Grossman, Brian Lenz, James Mond, Lawrence P Guiheen, Life Sciences Maste Perceptive, and Perceptive Advisors Llc. View insider buying and selling activity for ADMA Biologics. How do I buy shares of ADMA Biologics? Shares of ADMA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is ADMA Biologics' stock price today? One share of ADMA stock can currently be purchased for approximately $2.83. How big of a company is ADMA Biologics? ADMA Biologics has a market capitalization of $244.37 million and generates $29.35 million in revenue each year. The biotechnology company earns $-48,280,000.00 in net income (profit) each year or ($0.92) on an earnings per share basis. ADMA Biologics employs 314 workers across the globe. What is ADMA Biologics' official website? The official website for ADMA Biologics is www.admabiologics.com. How can I contact ADMA Biologics? ADMA Biologics' mailing address is 465 STATE ROUTE 17, RAMSEY NJ, 07446. The biotechnology company can be reached via phone at 201-478-5552 or via email at [email protected] This page was last updated on 7/12/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
